United Therapeutics at Cantor healthcare conference: fibrosis push widens

United Therapeutics (UTHR) presented a strategic shift from pulmonary hypertension to pulmonary fibrosis at the 12th Annual Cantor Fitzgerald Global Healthcare Conference. The company highlighted strong clinical data and a large pipeline for its nebulized Tyvaso, TETON-1 and TETON-2, describing their results as the best in pulmonary fibrosis in 30 years.

The FDA accepted the NDA for nebulized Tyvaso with a PDUFA date of April 26, 2027, and Phase III data for progressive pulmonary fibrosis expected in the second half of 2027. Management announced a $500 million accelerated stock repurchase and plans for 14 product launches between 2027 and 2029. The company aims to expand its addressable market 10-fold, reaching roughly 1 million U.S. patients in pulmonary fibrosis, IPF, PPF, and COPD with pulmonary hypertension.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.